Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
| Autor: | Berek K; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Auer M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Barket R; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Di Pauli F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Hocher J; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Krajnc N; Department of Neurology, Medical University of Vienna, Vienna, Austria.; Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria., Zinganell A; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Deisenhammer F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Berger T; Department of Neurology, Medical University of Vienna, Vienna, Austria.; Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria., Bsteh G; Department of Neurology, Medical University of Vienna, Vienna, Austria.; Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Jan; Vol. 30 (1), pp. 55-62. Date of Electronic Publication: 2023 Oct 18. |
| DOI: | 10.1177/13524585231201093 |
| Abstrakt: | Background: Odour discrimination and identification (DI) are markers associated with disability worsening and neuroaxonal damage in multiple sclerosis (MS). Objective: The main objective of this research is to investigate whether longitudinal change of DI predicts long-term MS disease course. Methods: This is a 6-year prospective longitudinal study on MS patients at the MS Clinic Innsbruck. Clinical, bi-annual visits assessed patients' history and Expanded Disability Status Scale (EDSS) score. DI and cognitive function were assessed at baseline (BL), Year 1 (Y1), Year 2 (Y2) and Year 6 (Y6) by the 'Sniffin' Sticks'/Symbol Digit Modalities Test. Results: Around 92 of 139 patients were available for Y6 follow-up. Mean DI scores significantly decreased over time (BL = 27.8, Y1 = 27.5, Y2 = 26.3 and Y6 = 26.3; p < 0.001) and negatively correlated with patients' age ( r Conclusion: Odour DI is an irreversible marker of neuroaxonal damage, associated with PIRA, cognitive deterioration and EDSS worsening. Competing Interests: Declaration of Conflicting InterestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: K.B. has participated in meetings sponsored by and received travel funding or speaker honoraria from Roche, Teva, Merck, Biogen, Sanofi and Novartis. H.H. has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Celgene, Janssen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva and received honoraria for acting as consultant for Biogen, Celgene, Novartis and Teva. He is associate editor of Frontiers in Neurology. M.A. received speaker honoraria and/or travel grants from Biogen, Merck, Novartis, Sanofi-Genzyme and Horizon Therapeutics. R.B. has participated in meetings sponsored by or received travel grants from, Novartis, Janssen-Cilag and Sanofi-Genzyme. Received honoraria from Janssen-Cilag.F.D.P. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. N.K. has participated in meetings sponsored by, received speaker honoraria or travel funding from BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). A.Z. has participated in meetings sponsored by, received speaking honoraria or travel funding from Biogen, Merck, Novartis, Sanofi-Genzyme and Teva. F.D. has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, Celgene, Merck, Novartis, Roche and Sanofi-Genzyme. His institution received scientific grants from Biogen and Sanofi-Genzyme.T.B. has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, Biologix, BMS/Celgene, Eisai, Janssen-Cilag, Jazz/GW, Horizon, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, UCB, Teva. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, BMS/Celgene, Merck, Novartis, Sanofi Aventis, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. G.B.: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|